Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13387598 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL984315 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL37472 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL8991654 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL11589654 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL8426647 | 0.97 | EPHX1 (0.60) | EPHX1CA12CA1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL11651995 | 0.94 | EPHX1 (0.58) | EPHX1CA12CA1CA2CA9 | |
| SCHEMBL1080505 | 0.94 | EPHX1 (0.58) | EPHX1CA12CA1CA2CA9 | |
| Hydrogen Peroxide SCHEMBL28079673 | 0.94 | EPHX1 (0.58) | EPHX1CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL6487536 | 0.94 | EPHX1 (0.58) | EPHX1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092187-A1 | OLEFIN POLYMERIZATION CATALYST COMPONENT HAVING CARBONATE COMPOUNDS | FORMOSAPLASTICSCORPORATION USA (US) | 2023-03-23 | — | — | US | claimed |
| CN-111393628-B | Application of organic metal complex and preparation method of polycarbonate prepolymer | 中国科学院过程工程研究所 | 2021-11-09 | — | — | CN | claimed |
| US-20200316575-A1 | Olefin Polymerization Catalyst Component Having Carbonate Compounds | FORMOSA PLASTICS CORP USA (US) | 2020-10-08 | — | — | US | claimed |
| CN-111393628-A | Application of organic metal complex and preparation method of polycarbonate prepolymer | 中国科学院过程工程研究所 | 2020-07-10 | — | — | CN | claimed |
| WO-2016151508-A1 | METHOD AND APPARATUS FOR THE PRODUCTION OF DIARYL CARBONATE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2016-09-29 | — | — | WO | claimed |
| EP-2217567-B1 | PEROXIDE COMPOSITION | DSM IP ASSETS BV (NL) | 2016-05-11 | — | — | EP | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250051259-A1 | METHOD FOR PRODUCING HIGHLY PURE DIARYL CARBONATE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240400496-A1 | METHOD FOR PRODUCING DIPHENYL CARBONATE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-5004827-A | Vaporizing a mixture of oxygen, carbon monoxide and an alcohol in the presence of a metal halide or a mixed metal halide impregnated on activated carbon | THE DOW CHEMICAL COMPANY (US) | 1991-04-02 | — | — | US | disclosed |
| EP-0269718-A4 | CATALYTIC VAPOR PHASE PROCESS FOR PRODUCING DIHYDROCARBYL CARBONATES. | DOW CHEMICAL CO (US) | 1988-10-17 | — | — | EP | disclosed |
| EP-0269718-A1 | CATALYTIC VAPOR PHASE PROCESS FOR PRODUCING DIHYDROCARBYL CARBONATES. | DOW CHEMICAL CO (US) | 1988-06-08 | — | — | EP | disclosed |
| WO-1987007601-A1 | CATALYTIC VAPOR PHASE PROCESS FOR PRODUCING DIHYDROCARBYL CARBONATES | THE DOW CHEMICAL COMPANY (US) | 1987-12-17 | — | — | WO | disclosed |
| US-4625044-A | Process of preparing dihydrocarbyl carbonates using a nitrogen-containing coordination compound supported on activated carbon | THE DOW CHEMICAL COMPANY (US) | 1986-11-25 | — | — | US | disclosed |
| US-4604242-A | Preparation of dialiphatic, dialicyclic, or di(aryl-substituted aliphatic) carbonates | THE DOW CHEMICAL COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| US-4490559-A | SYNTHESIS GAS AND A GROUP VII COMPOUND CATALYST | SHELL OIL COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051259-A1 | METHOD FOR PRODUCING HIGHLY PURE DIARYL CARBONATE | CA9, CA3, CEL | EPHX1 2730/4885CA12 15/4885CA1 8/4885 |
| US-20240400496-A1 | METHOD FOR PRODUCING DIPHENYL CARBONATE | HBB, HBG2, HBG1 | EPHX1 1985/4885CA12 21/4885CA1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.